Sonoma Pharmaceuticals (SNOA) Revenue (2010 - 2026)

Sonoma Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $6.4 million in Q2 2026.

• On a quarterly basis, Revenue rose 59.55% year-over-year to $6.4 million in Q2 2026; TTM through Jun 2026 was $21.9 million, a 47.0% increase from a year earlier, with the FY2026 full-year figure at $19.5 million, up 36.68% from the prior year.
• Revenue was $6.4 million for Q2 2026 at Sonoma Pharmaceuticals, up from $5.6 million in the prior quarter.
• The five-year high for Revenue was $6.4 million in Q2 2026, with the low at $2.3 million in Q1 2022.
• Average Revenue over 5 years is $3.8 million, with a median of $3.5 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Revenue retreated 18.01% in 2023, then jumped 59.55% in 2026.
• Over 5 years, Revenue stood at $2.9 million in 2022, then advanced by 6.59% to $3.1 million in 2023, then rose by 13.58% to $3.6 million in 2024, then advanced by 22.03% to $4.3 million in 2025, then soared by 47.3% to $6.4 million in 2026.
• The last three Revenue figures came in at $6.4 million (Q2 2026), $5.6 million (Q1 2026), and $4.3 million (Q4 2025), per Business Quant data.